1. Scrip
  2. >>Business

BMS Speeding Six More Programs Into Late-Stage R&D

Registrational Candidates Will Double Over 18 Months

 
• By Mandy Jackson

With big losses of exclusivity later in this decade, Bristol is looking to boost the number of products in its portfolio by 2030 even beyond the $35bn-plus in new revenue it already expects to bring in.

Bristol Myers Squibb Company is in a race against the clock as multiple blockbusters – including top-sellers Eliquis (apixaban) and Opdivo (nivolumab) – face losses of exclusivity over the next five years. The big pharma has nine new products that are expected to generate a combined $25bn-plus in sales by 2030 and six drug candidates in registrational trials that could add another $10bn or more in peak sales. And now the company will move another six programs into registrational trials during the next 18 months.

Key Takeaways

  • BMS is preparing for five products that altogether generated $27.8bn in 2022 sales to lose patent exclusivity between 2024 and 2028.

Bristol revealed its plans to advance those assets into later-stage clinical trials on 14 September when it hosted an R&D...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 
• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 
• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

More from Scrip

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 
• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.